Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 06 - 13 tags : Pharm-country save search
Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients
Published: 2022-06-13 (Crawled : 13:20) - biospace.com/
NVCT | $6.72 -0.59% -0.52% 81K
|
|
| O: 0.0%
H: 14.08%
C: 1.58%
nxp900 pharma preclinical positive cancer group pre-clinical train
Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience
Published: 2022-06-13 (Crawled : 13:20) - biospace.com/
ITCI | News 0 d | $72.0 -6.12% -6.5% 4.7M
|
Health Technology
|
| O: -3.38%
H: 5.17%
C: 3.59%
depression international therapy
BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
Published: 2022-06-13 (Crawled : 12:20) - biospace.com/
BRTX | $1.44 3.6% 3.14% 250K
|
Professional, Scientific, and T...
|
| O: -0.88%
H: 0.0%
C: -5.86%
disease trial therapy phase 2
Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene TherapyIssuance of U.S. Patent No. 11,351,225 Further Enhances Ocugen’s Gene Therapy Intellectual Property Portfolio
Published: 2022-06-13 (Crawled : 12:20) - biospace.com/
OCGN | News A | $1.32 -8.33% -9.51% 7.7M
|
Health Technology
|
| O: -6.28%
H: 0.0%
C: 0.0%
patent therapy
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
Published: 2022-06-13 (Crawled : 12:20) - biospace.com/
OPTN | $0.9277 -9.05% -9.76% 510K
|
Health Services
|
| O: 17.49%
H: 31.63%
C: 21.4%
treatment trial positive topline phase 3
Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies
Published: 2022-06-13 (Crawled : 12:20) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -3.12%
H: 0.0%
C: 0.0%
AKTX | $1.21 7.92% 8.47% 8.8K
|
Health Technology
|
| O: -0.99%
H: 3.0%
C: -1.1%
biotech therapeutics growth
Gainers vs Losers
| 60% | 40% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.